California 20252026 Regular Session Status: Introduced 1 R cosponsors

SB 1224 — The California Emerging Therapies Research Partnership Act.

Last action — August 13 hearing: Held in committee and under submission.

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed Assembly
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the Senate. Introduced February 19, 2026. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Stalled 28% · moderate confidence

  • Introduced

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

  • Single-party support

    Sponsorship is currently within one party (1 R).

  • Cleared a recorded vote

    Passed 6 recorded votes so far.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

The bill establishes a fund for research on certain emerging therapies and clinical trials in California.

This bill creates the California Emerging Therapies Research Partnership Fund to support research on emerging therapies like psilocybin and ketamine. It also sets up a partnership application with a federal agency to facilitate clinical trials and data sharing.

What this means for you
  • Workers: This bill may create opportunities for workers in the research and healthcare sectors as new trials are initiated.
  • Families: Families concerned about mental health treatments may see advancements through the research funded by this bill.
  • Environment: {}

Summary

Existing law, the California Uniform Controlled Substances Act, classifies controlled substances into 5 schedules and places the greatest restrictions and penalties on the use of substances placed in Schedule I. Existing law classifies, among others, psilocybin, ibogaine, and dimethyltryptamine as Schedule I substances, classifies ketamine as a Schedule III substance, and prohibits various actions related to those substances, including their sale, possession, transportation, manufacture, or cultivation. Existing law authorizes a person who is lawfully entitled to use specified controlled substances under applicable federal laws or regulations to obtain and use those substances for approved purposes in bona fide research, instruction, or analysis. This bill, the California Emerging Therapies Research Partnership Act, would establish the California Emerging Therapies Research Partnership Fund, a continuously appropriated fund, within the State Treasury, to be administered by the State Department of Health Care Services (department) and the Department of Veterans Affairs, to, among other things, issue grants to a University of California campus to serve as an anchor institution for a federally registered emerging therapies clinical trial. The bill would define "emerging therapies" for these purposes to mean psilocybin, ibogaine, 3,4-methylenedioxymethamphetamine, dimethyltryptamine, and ketamine when used in the context of a federally registered clinical trial, as specified. The bill would prohibit General Fund moneys from being deposited into the fund and would authorize the fund to receive federal grants, awards, and partnership payments and gifts, bequests, and philanthropic contributions made to the state, upon appropriation by the Legislature. The bill would prohibit the use of fund moneys for, among other things, purchasing, distributing, or administering a controlled substance. By creating a continuously appropriated fund, this bill would make an appropriation. This bill would require the California Health and Human Services Agency (agency) , in coordination with the department, the Department of Veterans Affairs, and the office of the President of the University of California, to submit a complete application for partnership designation to the federal Advanced Research Projects Agency for Health (ARPA-H) , as specified. The bill would require the department, within 90 days of receiving ARPA-H partnership designation, to execute a data-sharing memorandum of understanding with specified federal agencies to establish protocols for the sharing of deidentified, aggregated clinical trial outcome data. The bill would authorize specified legislative committees to request interim briefings from the agency on the status of the ARPA-H partnership application and would require the agency to respond to a request for briefing within 30 days. The bill would require the department to request that the University of California participate in specific activities. This bill would require the office of the President of the University of California to submit a readiness certification to the agency, the Department of Finance, and the Legislature, as specified. The bill would require the Department of Veterans Affairs to convene the California Veteran Emerging Therapies Research Advisory Council, with specified membership, to, among other things, serve as the primary advisory body to the department, the Department of Veterans Affairs, and the agency on matters relating to emerging therapies research for veterans and other priority populations. The bill would require the council to submit a needs assessment to the Department of Veterans Affairs, the agency, and the Legislature, as specified. The bill would require the agency to submit a federal readiness report to the Legislature and the Department of Finance, no later than January 1, 2028, that addresses, among other things, the status of California's ARPA-H partnership designation and the total amount of federal moneys received, as specified. This bill would provide that its provisions are severable.

Bill Text

Action History

  1. August 13 hearing: Held in committee and under submission.

  2. August 5 set for first hearing. Placed on suspense file.

  3. From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (June 30). Re-referred to Com. on APPR.

  4. Coauthors revised.

  5. From committee: Do pass and re-refer to Com. on M. & V.A. (Ayes 14. Noes 0.) (June 23). Re-referred to Com. on M. & V.A.

  6. Re-referred to Coms. on HEALTH and M. & V.A. pursuant to Assembly Rule 96.

  7. From committee with author's amendments. Read second time and amended. Re-referred to Com. on INS.

  8. Referred to Com. on INS.

  9. In Assembly. Read first time. Held at Desk.

  10. Read third time. Passed. (Ayes 39. Noes 0. Page 4526.) Ordered to the Assembly.

  11. Ordered to special consent calendar.

  12. Read second time. Ordered to third reading.

  13. From committee: Do pass as amended. (Ayes 7. Noes 0. Page 4269.) (May 14).

  14. Read second time and amended. Ordered to second reading.

  15. Set for hearing May 14.

  16. May 4 hearing: Placed on APPR. suspense file.

  17. Set for hearing May 4.

  18. From committee: Do pass and re-refer to Com. on APPR. (Ayes 7. Noes 0. Page 4012.) (April 22). Re-referred to Com. on APPR.

  19. From committee with author's amendments. Read second time and amended. Re-referred to Com. on INS.

  20. Set for hearing April 22.

  21. From committee with author's amendments. Read second time and amended. Re-referred to Com. on INS.

  22. Referred to Com. on INS.

  23. From printer. May be acted upon on or after March 22.

  24. Introduced. Read first time. To Com. on RLS. for assignment. To print.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 121 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (121)

121 members have not signed on to this bill.

Show all 121 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

Do pass and be re-referred to the Committee on [Appropriations]

Passed 8 Yea · 0 Nay
Party YeaNayPresentNot Voting
Democratic 5000
Unaffiliated 1000
Republican 2000
Total 8000
% of votes cast 100%0%0%0%
How each member voted (8)
Member Party Vote
Ávila Farías — Yea
Carrillo, Juan Democratic Yea
Irwin, Jacqui Democratic Yea
Quirk-Silva, Sharon Democratic Yea
Schiavo, Pilar Democratic Yea
Valencia, Avelino Democratic Yea
Davies, Laurie Republican Yea
Gonzalez, Jeff Republican Yea

Official roll call →

Do pass and be re-referred to the Committee on [Military and Veterans Affairs]

Passed 14 Yea · 0 Nay · 2 Other
Party YeaNayPresentNot Voting
Democratic 12000
Republican 2002
Total 14002
% of votes cast 88%0%0%13%
How each member voted (16)
Member Party Vote
Addis, Dawn Democratic Yea
Aguiar-Curry, Cecilia M. Democratic Yea
Ahrens, Patrick Democratic Yea
Bonta, Mia Democratic Yea
Caloza, Jessica Democratic Yea
Carrillo, Juan Democratic Yea
González, Mark Democratic Yea
Patel, Darshana R. Democratic Yea
Rodriguez, Celeste Democratic Yea
Schiavo, Pilar Democratic Yea
Sharp-Collins, LaShae Democratic Yea
Stefani, Catherine Democratic Yea
Gonzalez, Jeff Republican Yea
Johnson, Natasha Republican Not Voting
Patterson, Joe Republican Yea
Sanchez, Kate Republican Not Voting

Official roll call →

Special Consent

Passed 39 Yea · 0 Nay · 1 Other
Party YeaNayPresentNot Voting
Democratic 30000
Republican 9001
Total 39001
% of votes cast 98%0%0%3%
How each member voted (40)
Member Party Vote
Allen, Benjamin Democratic Yea
Archuleta, Bob Democratic Yea
Arreguín, Jesse Democratic Yea
Ashby, Angelique V. Democratic Yea
Becker, Josh Democratic Yea
Blakespear, Catherine S. Democratic Yea
Cabaldon, Christopher Democratic Yea
Caballero, Anna M. Democratic Yea
Cervantes, Sabrina Democratic Yea
Cortese, Dave Democratic Yea
Durazo, Maria Elena Democratic Yea
Gonzalez, Lena A. Democratic Yea
Grayson, Timothy S. Democratic Yea
Hurtado, Melissa Democratic Yea
Laird, John Democratic Yea
Limón, Monique Democratic Yea
McGuire, Mike Democratic Yea
McNerney, Jerry Democratic Yea
Menjivar, Caroline Democratic Yea
Padilla, Stephen C. Democratic Yea
Pérez, Sasha Renée Democratic Yea
Reyes, Eloise Gómez Democratic Yea
Richardson, Laura Democratic Yea
Rubio, Susan Democratic Yea
Smallwood-Cuevas, Lola Democratic Yea
Stern, Henry I. Democratic Yea
Umberg, Thomas J. Democratic Yea
Wahab, Aisha Democratic Yea
Weber Pierson, M.D., Akilah Democratic Yea
Wiener, Scott D. Democratic Yea
Alvarado-Gil, Marie Republican Yea
Choi, Steven S. Republican Yea
Dahle, Megan Republican Not Voting
Grove, Shannon Republican Yea
Jones, Brian W. Republican Yea
Niello, Roger W. Republican Yea
Ochoa Bogh, Rosilicie Republican Yea
Seyarto, Kelly Republican Yea
Strickland, Tony Republican Yea
Valladares, Suzette Martinez Republican Yea

Official roll call →

Subjects

housing veterans healthcare technology
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 1224 do?
Existing law, the California Uniform Controlled Substances Act, classifies controlled substances into 5 schedules and places the greatest restrictions and penalties on the use of substances placed in Schedule I. Existing law classifies, among others, psilocybin, ibogaine, and dimethyltryptamine as Schedule I substances, classifies ketamine as a Schedule III substance, and prohibits various actions related to those substances, including their sale, possession, transportation, manufacture, or cultivation. Existing law authorizes a person who is lawfully entitled to use specified controlled substances under applicable federal laws or regulations to obtain and use those substances for approved purposes in bona fide research, instruction, or analysis. This bill, the California Emerging Therapies Research Partnership Act, would establish the California Emerging Therapies Research Partnership Fund, a continuously appropriated fund, within the State Treasury, to be administered by the State Department of Health Care Services (department) and the Department of Veterans Affairs, to, among other things, issue grants to a University of California campus to serve as an anchor institution for a federally registered emerging therapies clinical trial. The bill would define "emerging therapies" for these purposes to mean psilocybin, ibogaine, 3,4-methylenedioxymethamphetamine, dimethyltryptamine, and ketamine when used in the context of a federally registered clinical trial, as specified. The bill would prohibit General Fund moneys from being deposited into the fund and would authorize the fund to receive federal grants, awards, and partnership payments and gifts, bequests, and philanthropic contributions made to the state, upon appropriation by the Legislature. The bill would prohibit the use of fund moneys for, among other things, purchasing, distributing, or administering a controlled substance. By creating a continuously appropriated fund, this bill would make an appropriation. This bill would require the California Health and Human Services Agency (agency) , in coordination with the department, the Department of Veterans Affairs, and the office of the President of the University of California, to submit a complete application for partnership designation to the federal Advanced Research Projects Agency for Health (ARPA-H) , as specified. The bill would require the department, within 90 days of receiving ARPA-H partnership designation, to execute a data-sharing memorandum of understanding with specified federal agencies to establish protocols for the sharing of deidentified, aggregated clinical trial outcome data. The bill would authorize specified legislative committees to request interim briefings from the agency on the status of the ARPA-H partnership application and would require the agency to respond to a request for briefing within 30 days. The bill would require the department to request that the University of California participate in specific activities. This bill would require the office of the President of the University of California to submit a readiness certification to the agency, the Department of Finance, and the Legislature, as specified. The bill would require the Department of Veterans Affairs to convene the California Veteran Emerging Therapies Research Advisory Council, with specified membership, to, among other things, serve as the primary advisory body to the department, the Department of Veterans Affairs, and the agency on matters relating to emerging therapies research for veterans and other priority populations. The bill would require the council to submit a needs assessment to the Department of Veterans Affairs, the agency, and the Legislature, as specified. The bill would require the agency to submit a federal readiness report to the Legislature and the Department of Finance, no later than January 1, 2028, that addresses, among other things, the status of California's ARPA-H partnership designation and the total amount of federal moneys received, as specified. This bill would provide that its provisions are severable.
Who sponsors SB 1224?
SB 1224 is sponsored by Jones, Brian W. (Republican).
What is the current status of SB 1224?
This bill has been introduced in the Senate. Introduced February 19, 2026. It must pass committee before a floor vote.
Where can I track SB 1224?
Track SB 1224 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 1224

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 1224

Last checked for changes about 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →